The American Astrazeneca menu to leave the British sealing puncture of 200 million pounds

Digest opened free editor

Rola Khaleda, FT editor, chooses her favorite stories in this weekly newsletter.

Astrazeneca is transferred to List her shares directly in New York The UK can cost up to 200 million pounds annually in a lost seal, and the treasury was estimated from the private sector.

The Kambridge -based drug group, the largest company at the FTSE 100, said on Monday that it was Raise the New York list In a plan that will give UK investors indirectly to the company.

This step, which has sparked more concerns about London’s position as a global position for menus, will strike the state treasures as HM Reseenue & Customs is no longer the collection of any closing fees related to the trading of the company’s shares in the United Kingdom. Treasury officials estimated that the result ranged between 170 million pounds and 200 million pounds, according to persons familiar with the situation.

Charles Hall, head of research at Peel Hunt, assumed that the government will face “200 million pounds to serve the closing of Astrazneca”.

“This is only a large number of one company that goes and you should be alert to others,” he said.

Hall said he had previously warned the government that it would face this strike months ago when there was speculation that Astrazneca in London would give up to New York, which was fueled by Sir Pascal Soreriot, the CEO, describing the work as a “very American company.”

The strike, which costs 200 million pounds, comes as the UK government seeks to raise funds for Blue the financial opening Before the budget in November. Astrazneca also comes as officials are trying to revive capital markets in London.

The collection of donations from public subscriptions in London fell to its lowest level in at least 30 years, Less capital has been raised this year than even the Angolan Stock Exchange. A series of companies recently transferred their lists to New York or returned to private ownership.

As Astrazneca will retain the Londers of London and Stockholm, they remain in FTSE and maintain its headquarters and the tax homeland in the United Kingdom, the company replaces US deposit receipts (ADRS) that has so far gave investors exposure to the company by moving to a full American list.

AdRS is less liquid and more difficult to trade than regular stocks and the new situation opens the company to a broader group of American shareholders. Meanwhile, investors in the UK will turn from registered shareholders to the holders of the interests of Astrazeneca, instead.

The company’s decision comes at a time when President Donald Trump puts pressure on the pharmaceutical industry to invest in the United States, and since drug makers are closed in a battle with UK government on prices.

The stock market analysts in the capital market said that the advertisement of Astrazeneca can push other listed companies with large American companies and shareholders to explore similar steps.

They also warned that the ability to take advantage of American liquidity without surrender could pave the time of the time of time to move widely away from the UK to some of the largest companies in the country.

The London Stock Exchange pressed repair Stamping fees The system, warning that it hinders the competitiveness of the United Kingdom. The cabinet is scheduled to present a closing holiday for new lists on LSE.

For 2023-24, Closing fee The receipts were close to 2.3 billion pounds, a decrease from about 2.6 billion pounds in the previous year, according to government data.

Astrazneca refused to comment.

The government said: “Astrazeneca asserting that it will remain listed, headquartered and paid in the UK, brings the long -awaited clarity, which is good news about jobs, growth and innovation,” the government said.

“It shows that British companies can expand the world and attract international investment – including from the American markets – and remain rooted in the United Kingdom.”

The assistants have also reported the creation of a lists for a lists, which they said was placed in place to help the government strategically communicate with the main players in the capital markets and work on ways to make the UK more attractive to the lists.